Pacira BioSciences, Inc. Common Stock

PCRXNASDAQUSD
25.61 USD
0.01 (0.04%)AT CLOSE (11:59 AM EDT)
25.62
0.01 (0.02%)
POST MARKET (AS OF 04:14 PM EDT)
Post Market
AS OF 04:14 PM EDT
25.62
0.01 (0.02%)
🔴Market: CLOSED

Shares of Pacira BioSciences, Inc. Common Stock (PCRX) are trading at $25.63. There is a divergence between signals — technical indicators rate "Buy" but underlying fundamentals lean "Sell". This is driven by a bullish Golden Cross on the moving averages and bullish moving average alignment. Valuation metrics suggest PCRX is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Jul 17, 2026.

Open?$25.58
High?$26.00
Low?$25.23
Prev. Close?$25.60
Volume?434.0K
Avg. Volume?480.7K
VWAP?$25.49
Rel. Volume?0.90x
Bid / Ask
Bid?$21.83 × 100
Ask?$29.10 × 100
Spread?$7.27
Midpoint?$25.47
Valuation & Ratios
Market Cap?1.0B
Shares Out?39.3M
Float?37.9M
Float %?93.7%
P/E Ratio?196.05
P/B Ratio?1.54
EPS?$0.13
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Employees
829
Market Cap
1.0B
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-02-03
Address
2000 SIERRA POINT PARKWAY
BRISBANE, CA 94005
Phone: 650-242-8052
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)? Bullish(+2/3)
Medium-Term (Wave)? Bullish(+1/3)
Short-Term (Ripple)? Bullish(+1/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
40
Z-Score?
33
Momentum?
35
Short Sent.?
19
Piotroski F-Score?4/9Mixed
Altman Z-Score?1.94Grey
Confidence?73%Moderate
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?17.37%High
Short Interest?6.6M
Days to Cover?11.7
Free Float37.9M
Avg Daily Volume565.4K
Settlement Date2026-06-30
Financial Health
Current Ratio?4.73Strong
Quick Ratio?3.35Strong
Cash Ratio?1.33Strong
Debt/Equity?0.56Moderate
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
89/100
P/E?
Peers
100
S&P
3
196.1PRICEY
P/B?
Peers
100
S&P
86
1.54CHEAP
P/S?
Peers
100
S&P
81
1.37CHEAP
P/FCF?
Peers
100
S&P
94
7.6CHEAP
EV/EBITDA?
Peers
100
S&P
76
10.7CHEAP
EV/Sales?
Peers
100
S&P
81
1.67CHEAP
Returns & Efficiency
ROE?
Peers
50
S&P
16
0.8%WEAK
ROA?
Peers
50
S&P
9
0.4%WEAK
Cash Flow & Enterprise
FCF?$132.7M
Enterprise Value?$1.2B
Fundamentals ratios updated end of day